Surrozen to Present at Upcoming Healthcare Investor Conference
Rhea-AI Summary
Surrozen (Nasdaq: SRZN) will present at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026 with a fireside chat at 1:10 PM ET / 10:10 AM PT. Interested parties can listen via a live audio webcast.
A replay will be archived on the company website for at least 30 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction – SRZN
In the Feb 26 session, SRZN declined 4.74%, reflecting a moderate negative market reaction. Argus tracked a trough of -6.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Investor conference | Neutral | -10.2% | Announcement of presentation at Guggenheim Emerging Outlook: Biotech Summit 2026. |
| Nov 25 | Investor conferences | Neutral | +2.7% | Participation in two early-December 2025 healthcare investor conferences with webcasts. |
| Nov 12 | Inducement option grant | Neutral | -6.3% | CFO received 50,000-share stock option grant under Nasdaq Listing Rule 5635(c)(4). |
| Nov 07 | Earnings and update | Negative | -3.3% | Q3 2025 financial results with net loss of $71.6M and no collaboration revenue. |
| Nov 05 | Investor conference | Neutral | +0.6% | Fireside chat at Guggenheim Healthcare Innovation Conference outlining Wnt-pathway programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Surrozen headlines, including conference appearances and earnings, have generally seen price moves that align directionally with the tone or neutrality of the news.
Over the last few months, Surrozen reported Q3 2025 results on Nov 7, 2025, highlighting focus on ophthalmology assets SZN-8141 and SZN-8143 and targeting an IND for SZN-8141 in 2026. It also disclosed an inducement option grant of 50,000 shares at $12.94 to the new CFO and multiple investor-conference presentations on Nov 12, 2025, early December 2025, and Feb 12, 2026. Today’s conference announcement fits this pattern of ongoing investor-engagement activity around its Wnt-pathway programs.
Key Terms
wnt signaling medical
ophthalmic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026
Fireside Chat at 1:10 PM Eastern Time / 10:10 AM Pacific Time
Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A replay of the webcasts will be archived on the website at www.surrozen.com for at least 30 days.
About Surrozen
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2024 filed, and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact
Email: Investorinfo@surrozen.com
